Core Viewpoint - The announcement of the FDA's acceptance of the IND application for LAE118 by 来凯医药-B has positively impacted the company's stock price, reflecting investor optimism about the potential of this new drug in treating specific cancer mutations [1]. Company Summary - 来凯医药-B's stock rose nearly 7% in early trading, currently up 5.88% at HKD 14.23, with a trading volume of HKD 9.3424 million [1]. - The FDA has accepted the clinical trial application for LAE118, a novel PI3Kα pan-mutant selective inhibitor developed by the company [1]. - LAE118 targets PIK3CA mutations commonly found in various cancers, including breast cancer, colorectal cancer, lung cancer, and endometrial cancer [1]. Industry Summary - Current global PI3Kα inhibitors lack selectivity for mutant types, showing strong activity against wild types, which leads to poor tolerance and a high likelihood of developing resistance [1].
港股异动 | 来凯医药-B(02105)涨近7% LAE118新药临床试验申请获FDA受理